Get the Daily Brief
Latest Biotech News
Lilly’s triple‑agonist retatrutide wins Phase III endpoints – Major A1C and weight gains reported
Eli Lilly reported positive top‑line results from Transcend‑T2D‑1: the triple‑agonist retatrutide produced clinically meaningful A1C reductions and substantial weight loss in people with type 2...
FDA widens rare‑obesity label; J&J gets oral IL‑23 pill — regulators clear niche and mainstream drugs
The FDA expanded the label for Rhythm Pharmaceuticals’ Imcivree to include adults and children aged 4 and up with acquired hypothalamic obesity, making it the first approved therapy for that...
CAR‑T made inside the patient: Dual‑vector in vivo integration shows tumor clearance in preclinical models
Researchers at UCSF reported a dual‑vector approach that enables programmable, site‑specific integration of large DNA payloads into T cells in vivo, producing functional CAR‑T cells without ex...
Generalist biological AI... and a trillion‑gene push: Big data meets drug design
Nature Biotechnology published a review mapping a vision for generalist biological AI—models capable of performing diverse tasks across biological domains rather than narrow, single‑use tools. The...
AstraZeneca doubles down on China: Cell‑therapy R&D and manufacturing hub goes ahead
AstraZeneca revealed plans to build an end‑to‑end cell‑therapy R&D and manufacturing base in Shanghai and to establish an innovation center with early‑stage research and regulatory support. The...
Decentralized diagnostics: Diasorin distribution deal and WHO’s new TB nPOC‑NAAT class
Diasorin signed a distribution agreement with McKesson Medical Surgical to push its Liaison Nes point‑of‑care PCR system into non‑acute settings, including physician office labs and decentralized...
Congress revives SBIR/STTR seed funding – Biotech early‑stage lifeline restored
Congress reauthorized the SBIR and STTR programs, restoring federal seed funding for small businesses and research teams after a lapse. The bipartisan action preserves critical early‑stage grant...
Congruence raises fresh capital as it starts human trials – Protein‑misfolding correctors advance
Congruence Therapeutics closed a $39.5 million financing round to advance a portfolio of small‑molecule correctors targeting protein‑misfolding diseases into the clinic. The funding follows the...
Programmable in vivo CAR‑T: Dual‑vector system inserts large DNA payload
Researchers at UCSF reported a method to generate CAR T cells directly inside living hosts by delivering a large DNA sequence and achieving site-specific integration with a dual‑vector approach....
Retatrutide: triple‑agonist slashes A1C and sheds 36.6 lbs in Phase III
Eli Lilly disclosed top‑line results from a phase III trial showing retatrutide, a triple agonist targeting GLP‑1, GIP and glucagon receptors, produced substantial glycemic control and weight loss...
FDA greenlights high‑dose Wegovy — approval fast‑tracked by commissioner’s voucher
The FDA approved a 7.2 mg high‑dose formulation of Novo Nordisk’s semaglutide injection (Wegovy HD) under a commissioner’s voucher that expedited review to roughly 54 days. Novo won clearance for...
J&J's Icotyde: FDA clears oral IL‑23 pill for plaque psoriasis
Johnson & Johnson and Protagonist won FDA approval for Icotyde (icotrokinra), the first oral IL‑23 receptor antagonist cleared for moderate‑to‑severe plaque psoriasis in adults and adolescents....
Nautilus Voyager lands Baylor: single‑molecule proteomics enters cancer research
Nautilus Biotechnology opened early access to its Voyager single‑molecule proteomics platform by naming Baylor College of Medicine its first customer in an early access program. Baylor will use...
Collegium buys AZSTARYS from Corium for $650m — ADHD play
Collegium Pharmaceutical agreed to acquire Corium Therapeutics’ FDA‑approved ADHD product AZSTARYS for $650 million upfront plus up to $135 million in milestones to expand its neuropsychiatric...
Verily raises $300m; Alphabet cedes majority control
Verily closed a $300 million funding round that reduced Alphabet’s ownership and ended its majority control of the healthcare‑focused unit. The Series X‑led capital infusion brings new outside...
TerraPower to build $450m actinium‑225 plant — nuclear supply for radiotherapies
TerraPower Isotopes announced plans to build an actinium‑225 production facility in Philadelphia with a projected $450 million cost and production start targeted for 2029. The company said the...
Gilead hands HBV candidate back to Assembly — ABI‑4334 rights revert
Gilead informed Assembly Biosciences that it would not exercise its option for the next‑generation hepatitis B capsid assembly modulator ABI‑4334, returning full rights to Assembly. The move...
Arvinas PROTAC penetrates brain: ARV‑102 halves LRRK2 in CSF
Arvinas presented Phase 1 data showing oral PROTAC ARV‑102 achieved approximately ≥50% reduction of LRRK2 protein in cerebrospinal fluid after 14 days and maintained reduction through 28 days in...
Lilly’s triple‑agonist posts phase III win — A1C down, dramatic weight loss
Eli Lilly reported positive top-line results from Transcend‑T2D‑1, a phase III trial of retatrutide, a first‑in‑class GIP/GLP‑1/glucagon triple agonist. The study showed clinically meaningful A1C...
FDA clears high‑dose Wegovy — Novo uses commissioner voucher for rapid review
The FDA approved Wegovy HD, a 7.2 mg once‑weekly formulation from Novo Nordisk, after an accelerated review under the commissioner's voucher program that cut the decision timeline to roughly 54...